

## UNIVERSITY OF JAFFNA, SRI LANKA BACHELOR OF PHARMACY SECOND YEAR SECOND SEMESTER EXAMINATION-April 2020 PHARMACOLOGY & PHARMACOTHERAPY II – PHACL 2242 Paper II

Date: 24.09.2020 Time: 02 hours

## ANSWER ALL FOUR QUESTIONS

| 1. |      |   |            |
|----|------|---|------------|
|    | 1.1. | List four (04) groups of diuretic agents with one example for |            |
|    |      | each group.   | (20 Marks) |
|    | 1.2. | Describe the mechanism of action of furosemide.               | (30 Marks) |
|    | 1.3. | Explain the pharmacological basis of using furosemide in      |            |
|    |      | heart failure.  | (30 Marks) |
|    | 1.4. | List the adverse effects of furosemide.                       | (20 Marks) |
| 2. |      |   |            |
|    | 2.1. | List three cholinesters.                                      | (15 Marks) |
|    | 2.2. | List the therapeutic uses of cholinergic drugs.               | (15 Marks) |
|    | 2.3. | Describe the mechanism of action of anticholinesterases/      |            |
|    |      | cholinesterase inhibitors.                                    | (20 Marks) |
|    | 2.4. | List the symptoms of organophosphates poisoning.              | (20 Marks) |
|    | 2.5. | Describe the management of organophosphate poisoning.         | (30 Marks) |
| 3. |      |   |            |
|    | 3.1. | Describe the mechanism of action of heparin.                  | (20 Marks) |
|    | 3.2. | List the advantages of enoxaparin compared to conventional    |            |
|    |      | heparin.  | (20 Marks) |
|    | 3.3. | List the indications for warfarin.                            | (20 Marks) |
|    | 3.4. | Discuss the drug-drug and drug-food interactions associated   |            |
|    |      | with warfarin therapy.  | (40 Marks) |
|    |      |   |            |
| 4. |      | Write an account on   |            |
|    | 4.1. | Oral iron therapy.  | (30 Marks) |
|    | 4.2. | Inhaled medications in the long term management of            | (30 Marks) |
|    |      | asthma.   |            |
|    | 4.3. | HMG-CoA reductase inhibitors.                                 | (40 Marks) |